Targeting αvβ3 and α5β1 for gene delivery to proliferating VSMCs: Synergistic effect of TGF-β1

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 285, Issue 3 54-3, 2003, Pages

  Li, Jian Mei ^a   Fan, Lampson M ^a   Shah, Ajay ^a   Brooks, Gavin ^b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

^c School of Animal and Microbial Sciences   (United Kingdom)

Author keywords

Integrin; Molossin rector; Peptide vector

Indexed keywords

ALPHA VBETA3 INTEGRIN; BETA GALACTOSIDASE; FUSOGENIC PEPTIDE; GAMMA INTERFERON; INTEGRIN; LIPOFECTAMINE; LUCIFERASE; LYSINE; PEPTIDE; PLATELET DERIVED GROWTH FACTOR BB; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; MOLOSSIN PEPTIDE; OLIGOPEPTIDE; TGFB1 PROTEIN, HUMAN; TGFB1 PROTEIN, RAT; TRANSFORMING GROWTH FACTOR BETA; VITRONECTIN RECEPTOR;

AORTA; ARTICLE; BLOOD VESSEL INJURY; BYPASS SURGERY; CELL CULTURE; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; DNA VECTOR; ENDOTHELIUM INJURY; ENZYME ACTIVITY; GENE DELIVERY SYSTEM; GENE EXPRESSION; HUMAN; HUMAN CELL; MOLOSSIN VECTOR; NONVIRAL GENE DELIVERY SYSTEM; ORGAN CULTURE; PRIORITY JOURNAL; REPORTER GENE; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; CELL DIVISION; CYTOLOGY; DRUG POTENTIATION; GENE TRANSFER; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; METHODOLOGY; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY;

AORTA; CELL DIVISION; CELLS, CULTURED; DRUG SYNERGISM; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INTEGRIN ALPHA5BETA1; INTEGRIN ALPHAVBETA3; MUSCLE, SMOOTH, VASCULAR; OLIGOPEPTIDES; ORGAN CULTURE TECHNIQUES; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0041357210     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00103.2003     Document Type: Article

References (31)

1. Baek S and March KL. Gene therapy for restenosis getting nearer the heart of the matter. Circ Res 82: 295-305, 1998.
2. Barry MA, Dower WJ, and Johnston SA. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nature Medicine 2: 299-305, 1996.
3. Basson CT, Kocher O, Basson MD, Asis A, and Madri JA. Differential modulation of vascular cell integrin and extracellular matrix expression in vitro by TGF-β1 correlates with reciprocal effects on cell migration. J Cell Physiol 153: 118-128, 1992.
4. Bobik A, Agrotis A, Kanellakis P, Dilley R, Krushinsky A, Smirnov V, Tararak E, Condron M, and Kostolias G. Distinct patterns of transforming growth factor-β isoform and receptor expression in human atherosclerotic lesions. Circulation 99: 2883-2891, 1999.
5. Bui M, Ojala PM, and Whittaker G. Cells and viruses: an infectious relationship. Trends Cell Biol 6: 199-201, 1996.
6. Collins L, Gustafsson K, and Fabre JW. Tissue-binding properties of a synthetic peptide DNA vector targeted to cell membrane integrins. Transplantation 69: 1041-1050, 2000.
7. Coonrod A, Li FQ, and Horwitz M. On the mechanism of DNA transfection: efficient gene transfer without viruses. Gene Therapy 4: 1313-1321, 1997.
8. Durante W, Liao L, Reyna SV, Peyton KJ, and Schafer AI. Transforming growth factor-β1 stimulates L-arginine transport and metabolism in vascular smooth muscle cells. Circulation 103: 1121-1127, 2001.
9. Dzau VJ, Mann MJ, Morishita R, and Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 93: 11421-11425, 1996.
10. Hart SL, Collins L, Gustasson K, and Fabre JW. Integrin-mediated transfection with peptides containing argine-glycine-aspartic acid domains. Gene Therapy 4: 1225-1230, 1997.
11. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25, 1992.
12. Janat MF, Argraves WS, and Liau G. Regulation of vascular smooth muscle cell integrin expression by transforming growth factor-β1 and by platelet-derived growth factor-BB. J Cell Physiol 151: 588-595, 1992.
13. Kanda S, Kuzuya M, Ramos MA, Koike T, Yoshino K, Ikeda S, and Iguchi A. Matrix metalloproteinase and αvβ3 integrin-dependent vascular smooth muscle cell invasion through a type I collagen lattice. Arterioscler Thromb Vasc Biol 20: 998-1005, 2000.
14. Li JM, Collins L, Zhang X, Gustafsson K, and Fabre JW. Efficient gene delivery to vascular smooth muscle cells using a nontoxic synthetic peptide vector system targeted to membrane integrins: a first step toward the gene therapy of chronic rejection. Transplantation 70: 1616-1624, 2000.
15. Libby P. Gene therapy of restenosis promise and perils. Circ Res 82: 404-406, 1998.
16. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, Orav EJ, Ehsan A, Dell'Acqua G, and Dzau VJ. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 354: 1493-1498, 1999.
17. Pickering JG, Chow LH, Li S, Rogers KA, Rocnik EF, Zhong R, and Chan BMC. α5β1 Integrin expression and luminal edge fibronectin matrix assembly by smooth muscle cells after arterial injury. Am J Pathol 156: 453-465, 2000.
18. Pittet JF, Griffiths MJD, Geiser T, Kaminski N, Dalton SL, Huang X, Brown LAS, Gotwals PJ, Koteliansky VE, Matthay MA, and Sheppard D. TGF-β is a critical mediator of acute lung injury. J Clin Invest 107: 1537-1544, 2001.
19. Plank C, Oberhauser KM, Koch C, and Wagner E. The INF-luence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. J Biol Chem 269: 12918-12924, 1994.
20. Qian HS, Channon K, Neplioueva V, Wang Q, Finer M, Tsui L, George SE, and McArthur J. Improved adenoviral vector for vascular gene therapy. Circ Res 88: 911-917, 2001.
21. Ruoslahti E and Obrink B. Common principles in cell adhesion. Exp Cell Res 227: 1-11, 1996.
22. Scarborough RM, Rose JW, Naughton MA, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, and Charo IF. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem 268: 1058-1065, 1993.
23. Shattil SJ and Ginsberg MH. Perspective series: cell adhesion in vascular biology. Integrin signaling in vascular biology. J Clin Invest 100: 1-5, 1997.
24. Shewring L, Collins L, Lightman SL, Hart S, Gustafsson K, and Fabre JW. A nonviral vector system for efficient gene transfer to corneal endothelial cells via membrane integrins. Transplantation 64: 763-769, 1997.
25. Slepian MJ, Massia SP, Dehdashti B, Fritz A, and Whitesell L. β3-Integrins rather than β1-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration. Circulation 97: 1818-1827, 1998.
26. Smith JD, Bryant SR, Couper LL, Vary CPH, Gotwals PJ, Koteliansky VE, and Lindner V. Soluble transforming growth factor-β type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 84: 1212-1222, 1999.
27. Smith JW, Vestal DJ, Irwin SV, Burke TA, and Cheresh DA. Purification and functional characterization of integrin αvβ5. J Biol Chem 265: 11008-11013, 1990.
28. Thyberg J. Differentiated properties and proliferation of arterial smooth muscle cells in culture. Internat Rev Cytol 169: 183-265, 1996.
29. Yamamoto K, Morishita R, Tomita N, Shimozato T, Nakagami H, Kikuchi A, Aoki M, Higaki J, Kaneda Y, and Ogihara T. Ribozyme oligonucleotides against transforming growth factor-β inhibited neointimal formation after vascular injury in rat model. Circulation 102: 1308-1314, 2000.
30. Zhang X, Collins L, and Fabre JW. A powerful cooperative interaction between a fusogenic peptide and lipofectamine for the enhancement of receptor-targeted, nonviral gene delivery via integrin receptors. J Gene Med 3: 560-568, 2001.
31. Zhang X, Collins L, Sawyer GJ, Dong X, Qiu Y, and Fabre JW. In vivo gene delivery via portal vein and bile duct to individual lobes of the rat liver using a polylysine-based nonviral DNA vector in combination with chloroquine. Human Gene Therapy 12: 2179-2190, 2001.